CytomX Therapeutics to Present at Upcoming Investor Conferences
CytomX Therapeutics will participate in three high-profile investor conferences in New York this September, including Cantor’s Global Healthcare Conference,...
VTV Therapeutics Secures Mammoth $80M Private Placement
vTv Therapeutics has secured an $80 million PIPE to fund the ongoing CATT1 phase 3 trial and continued development...
Idorsia’s Quviviq Launches in China, Fuels Global Growth
Simcere has launched Quviviq (daridorexant) in mainland China for adult insomnia, adding one of the leading dual orexin receptor...
EU Panel Backs Dupixent for Chronic Spontaneous Urticaria
Europe’s drug regulator has issued a positive opinion for dupilumab in chronic spontaneous urticaria, recommending approval for adults and...
Arecor Inks Co-Development Deal, Sells Royalty Rights
Arecor Therapeutics has struck a co-development deal with Sequel Med Tech to pair AT278, its ultra-concentrated (500 U/mL), ultra-rapid...
Basilea Awarded BARDA Contract for a Promising New Antibiotic
Basilea Pharmaceutica has secured a BARDA contract novation to support the development of ceftibuten–ledaborbactam etzadroxil, an investigational oral beta-lactam/beta-lactamase...
25 Results Confirm the Relevance of Roquette’s Strategy
Roquette has closed the acquisition of IFF Pharma Solutions and reported first-half 2025 results showing a step-change in mix...
Merck’s Verona Pharma Acquisition Gets Shareholder Approval
Verona Pharma shareholders have approved Merck’s proposed acquisition of the company for $107 per American Depositary Share, valuing the...
Eurobio Scientific’s First Semester Fiscal 2025 Results
Eurobio Scientific reported first-half 2025 revenue of €81.2 million, up 10% year over year, with proprietary products rising to...
Briumvi Data: 90% Free of MS Disability Progression at 6 Yrs
TG Therapeutics reported six-year outcomes for Briumvi (ublituximab) from the ULTIMATE I & II Phase 3 programs at ECTRIMS...